Core Viewpoint - The article discusses the challenges in finding equity income, highlighting low dividend yields in both the US and global markets, and emphasizes the importance of companies with strong dividend histories and wide economic moats for steady income generation [1][2][4]. Dividend Yield Trends - The Morningstar US Market Index had a dividend yield of under 1.2% in Q1 2026, which is historically low, while the Morningstar Global Markets ex-US Index offered a yield of 2.6% [1]. - Stock prices have increased significantly, but dividend payments have not kept pace, with a notable shift towards share buybacks and investments in artificial intelligence [2]. Sector Performance - There has been a rebound in sectors such as industrials, energy, and consumer defensives, which has supported total returns but kept yields lower [3]. - Dividend-paying stocks outside the U.S. have outperformed the broader market for some time, with around 1,500 companies globally under analyst coverage and assigned moat ratings [3]. Moat Analysis - Companies with wide moats tend to sustain profitability more consistently and have historically cut dividends less often compared to those with narrow or no moats [4]. Methodology for Stock Selection - The selection criteria for the list of dividend stocks included companies that have raised dividends for at least 10 consecutive years and have yields above 0.5% as of March 19 [6]. Company Highlights - **Eli Lilly and Company (NYSE: LLY)**: - Dividend yield as of March 19 is 0.75%. Recent study results for retatrutide indicate it may be a viable option for patients prioritizing weight loss, with projected 2030 sales at $4.9 billion [9][10][11]. - **S&P Global Inc. (NYSE: SPGI)**: - Dividend yield as of March 19 is 0.91%. The price recommendation was raised to $495, citing stronger issuance trends, with February billed issuance rising 22% year-over-year [12][13]. - The acquisition of Enertel AI Corporation enhances S&P Global's capabilities in AI-driven power price forecasting, providing a more comprehensive view of the power market [14][15].

England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...

In this article, we will look at the 12 Best Long Term Stocks to Invest In According to Billionaires.On March 17, Ed Yardeni, Yardeni Research president, appeared on CNBC’s ‘Squawk Box’ to talk about the impact of the Iran war, the latest market trends, and the state of the economy.He says he is more risk-averse, at least for the near-term, and stated that everybody on Wall Street is trying to be a military expert in this fog of war, when actually, even the military experts cannot accurately predict where t ...

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival Eli Lilly. Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly's obesity drug Z ...

Novo Nordisk won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly's competing shot Zepbound https://t.co/pUCnYjWVYd ...

整理 | GLP1减重宝典内容团队 礼来在代谢赛道又向前推了一步。 3月19日，礼来宣布，其GIPR/GLP-1R/GCGR三靶点激动剂 Retatrutide 在III期 TRANSCEND-T2D-1 研究中取得积极结果。该研究主要评估 Retatrutide 作为饮食和运动基础上的辅助治疗，用于仅靠生活方式干预仍无法良好控糖的2型糖尿病成人患者时的疗效与安全性。 从公布的数据来看，这款每周一次给药的三靶点药物，不仅达成了主要终点，也完成了所有关键次要终点。40周治疗后，Retatrutide 相较安慰 剂，在降糖和减重两大核心指标上都显示出明显优势。 其中，在主要终点方面，按疗效估计目标分析，接受 Retatrutide 治疗的患者，糖化血红蛋白 A1C 平均最高下降达到 2.0%。而在关键次要终点 方面，患者平均减重最高达到 36.6 磅，约合 16.8%。更值得注意的是，减重趋势在整个治疗过程中并未提前触顶，而是持续到研究结束。 除了血糖和体重这两项最受关注的指标，Retatrutide 在心血管代谢风险因素上也交出了不错的答卷。礼来表示，该药还带来了非高密度脂蛋白 胆固醇、甘油三酯以及收缩压等指标 ...

Patients On Lilly’s Experimental Diabetes Drug Lost 15% Of Their Weight And Lowered Blood Sugar, Company Sayshttps://t.co/ywt309vSxh https://t.co/aZiJf5Qpmu ...

Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt ...

Core Insights - Eli Lilly's next-generation obesity drug retatrutide has successfully completed its first late-stage trial for Type 2 diabetes patients, demonstrating significant improvements in blood sugar management and weight loss [1][2][3] Group 1: Drug Efficacy - Retatrutide reduced hemoglobin A1c levels by an average of 1.7% to 2% at 40 weeks compared to placebo, achieving the primary study goal [1] - At the highest dose, retatrutide helped patients lose an average of 16.8% of their weight, equating to 36.6 pounds, over 40 weeks [2] - The drug's A1C reduction, while not the highest in Lilly's portfolio, is still considered strong compared to other diabetes medications that do not target gut hormones [6] Group 2: Patient Experience and Safety - The discontinuation rate due to side effects was relatively low, at up to 5%, indicating a favorable safety profile [3] - Common side effects included gastrointestinal issues, with 26.5% of patients experiencing nausea, and lower rates for diarrhea and vomiting [10] Group 3: Competitive Landscape - Retatrutide is positioned as a key component of Lilly's obesity portfolio, alongside its existing drug Zepbound and the upcoming orforglipron [4] - Novo Nordisk is developing a competing drug that also targets multiple hunger-regulating hormones, but it is still in earlier stages of development [12][13] Group 4: Market Strategy - Lilly plans to report findings from seven additional phase three trials by the end of the year, although it has not yet filed for approval for retatrutide [5] - The company emphasizes the importance of having multiple treatment options for obesity and diabetes, as individual patient needs may vary [7][8]

当外界还在争论AI究竟只是药物研发的"辅助工具"还是能颠覆整个产业时，全球制药巨头们已经用真金白银做出了选择。 3月16日，罗氏宣布扩展其全球人工智能基础设施，正式部署由英伟达最新一代加速计算技术驱动的"人工智能工厂"。此次在美国和欧洲完成 了2176个高性能GPU的部署，使其本地和云端GPU基础设施总容量超过3500个Blackwell GPU。 罗氏声称，这是目前已公布的制药公司可用的最大GPU规模。 这并非个例。就在一个月前，礼来也正式启用了其医药AI工厂"LillyPod"，内置了1016颗英伟达Blackwell Ultra GPU，整体算力高达9000 Petaflops。更早之前，礼来与英伟达宣布将在五年内投入超10亿美元建立AI联合创新实验室。 当传统的"双十定律"（十年时间、十亿美元）愈发成为难以承受之重，AI被寄予厚望，成为打破僵局的那把钥匙。一场围绕"算力"和"AI基础 设施"的竞赛，正在全球顶尖药企之间悄然打响。 然而，21世纪经济报道记者在深入调研中发现，尽管赛道持续火热，融资额激增，但AI制药行业当下正处于一个充满矛盾的关键时期：巨头 疯狂扩张，资本理性回归，技术验证在即，商业痛点 ...